Neurological complications following functional neck dissection

Prim, M.P.; Diego, Juan Albarrán; Verdaguer, José María; Sastre, Noelia; Rabanal, I.

doi:10.1007/s00405-005-1028-9

Cited by 82 publications

(66 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11 It could be demonstrated that the incidence of an impairment of the marginal facial nerve in cases of a neck dissection is equal to the frequency after extirpation of the submandibular gland in the context of a benign disease. 12 In the present study, in none of the cases with dissection of level I could an impairment of the facial nerve be observed.…”

Section: Discussionmentioning

confidence: 98%

Postoperative morbidity after different types of selective neck dissection

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Postoperative morbidity after different types of selective neck dissection

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The Methodological Index for Non-Randomized Studies (MINORS) criterion was used. 6 This score quantifies the study quality based on 8 items-0, 1, or 2 points were assigned per item-up to a maximum score of 16 points. We considered 30 or more months of mean follow-up as adequate (2 points) and less than 30 months as suboptimal (1 point); zero points were given if no follow-up time was mentioned.…”

Section: Quality Assessmentmentioning

confidence: 99%

Sentinel Node Biopsy for Head and Neck Melanoma

Rosa

Lyman

Silbermins

et al. 2011

Otolaryngol.--head neck surg.

119

View full text Add to dashboard Cite

Objective. This systematic review was conducted to examine the test performance of sentinel node biopsy in head and neck melanoma, including the identification rate and false-negative rate.Data Sources. PubMed, EMBASE, ASCO, and SSO database searches were conducted to identify studies fulfilling the following inclusion criteria: sentinel node biopsy was performed, lesions were located on the head and neck, and recurrence data for both metastatic and nonmetastatic patients were reported.Review Methods. Dual-blind data extraction was conducted. Primary outcomes included identification rate and test performance based on completion neck dissection or nodal recurrence.Results. A total of 3442 patients from 32 studies published between 1990 and 2009 were reviewed. Seventy-eight percent of studies were retrospective and 22% were prospective. Trials varied from 9 to 755 patients (median 55). Mean Breslow depth was 2.53 mm. Median sentinel node biopsy identification rate was 95.2%. More than 1 basin was reported in 33.1% of patients. A median of 2.56 sentinel nodes per patient were excised. Sentinel node biopsy was positive in 15% of patients. Subsequent completion neck dissection was performed in almost all of these patients and revealed additional positive nodes in 13.67%. Median follow-up was 31 months. Across all studies, predictive value positive for nodal recurrence was 13.1% and posttest probability negative was 5%. Median false-negative rate for nodal recurrence was 20.4%. Conclusion.Sentinel node biopsy of head and neck melanoma is associated with an increased false-negative rate compared with studies of non-head and neck lesions. Positive sentinel node status is highly predictive of recurrence.Keywords head and neck melanoma, sentinel lymph node biopsy, falsenegative rate, systematic review Received September 30, 2010; revised March 29, 2011; accepted April 6, 2011. A n estimated 68,130 new cases of malignant melanoma were predicted to be diagnosed in 2010, resulting in 8700 deaths.1 Approximately 20% of primary lesions are located on the head and neck. Mortality rates among head and neck melanomas differ by site; lesions of the scalp and neck have the highest mortality, with a 10-year survival of 60%. Tumors located on the ear, face, and eyelid have 10-year survival rates of 70%, 80%, and 90%, respectively. 2Occult lymph node metastasis is present in 15% to 20% of patients with melanoma of the head and neck and clinically negative nodes.3,4 Elective lymph node dissection (ELND) has been used to stage melanoma of the head and neck in these patients; however, morbidity associated with ELND includes cranial nerve XI transection, marginal nerve injury, and chyle leak.5-8 Furthermore, no clear survival benefit has been shown with ELND. 9 The Intergroup Melanoma Trial, a randomized controlled trial by Balch et al, 9 included patients with head and neck melanoma in combination with truncal melanomas and analyzed the survival difference between ELND and a "watch and wait" algorithm. This study showed no su...

show abstract

“…Prim et al reported the incidence of neurological complications following functional neck dissection for the treatment of laryngeal and/or hypopharyngeal carcinoma [12]. In their study, the incidence of neurological sequelae was 1.26% and 0.42% in the marginal branch of the facial nerve and hypoglossal nerve, respectively.…”

Section: Discussionmentioning

confidence: 97%

Therapeutic selective neck dissection (level II–V) for node-positive hypopharyngeal carcinoma: is it oncologically safe?

Lim

Lee

Choi

2009

Acta Oto-Laryngologica

View full text Add to dashboard Cite

Conclusions. Our study suggests that routine level I dissection may not be necessary in the surgical management of clinically N'hypopharyngeal squamous cell carcinoma (SCC) in patients who do not have a positive lymph node in neck level I. Objective. To determine whether level I lymph node dissection can be saved in patients with clinically N'hypopharyngeal SCC. Patients and methods. Retrospective analysis of 64 consecutive clinically N'patients with untreated hypopharyngeal SCC between 1994 and 2006. Forty-seven patients underwent level I lymph node dissection and the remaining 17 did not. Forty-five of the 64 patients were followed for a minimum of 2 years, if alive, or until death. Of these 45 patients, 35 underwent ipsilateral level I dissection of the neck. Results. The incidence of occult metastases to level I was 6% (3 of 47). Six (17%) of 35 patients with level I dissection and 1 (10%) of 10 patients without level I dissection experienced regional recurrence (p0.05). The 2-year disease-specific survival in 47 patients undergoing level I neck dissection was 44% compared with 37% in 17 patients who did not undergo level I neck dissection (p 0.05).

show abstract

Neurological complications following functional neck dissection

Cited by 82 publications

References 14 publications

Postoperative morbidity after different types of selective neck dissection

Postoperative morbidity after different types of selective neck dissection

Sentinel Node Biopsy for Head and Neck Melanoma

Therapeutic selective neck dissection (level II–V) for node-positive hypopharyngeal carcinoma: is it oncologically safe?

Contact Info

Product

Resources

About